Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12744MR)

This product GTTS-WQ12744MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12744MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11263MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ14076MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ4615MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ9337MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ3515MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ9879MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ3645MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ11845MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW